Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Merck
Citi
Deloitte
Healthtrust
Federal Trade Commission
Dow
Teva
Baxter
Harvard Business School

Generated: January 21, 2018

DrugPatentWatch Database Preview

Valeant Luxembourg Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT LUXEMBOURG, and what generic alternatives to VALEANT LUXEMBOURG drugs are available?

VALEANT LUXEMBOURG has six approved drugs.

There is one US patent protecting VALEANT LUXEMBOURG drugs.

There are fifty-two patent family members on VALEANT LUXEMBOURG drugs in seventeen countries and nine supplementary protection certificates in seven countries.

Summary for Valeant Luxembourg
International Patents:52
US Patents:1
Tradenames:4
Ingredients:5
NDAs:6

Drugs and US Patents for Valeant Luxembourg

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Luxembourg GRIFULVIN V griseofulvin, microsize TABLET;ORAL 062279-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg GRIFULVIN V griseofulvin, microcrystalline TABLET;ORAL 062279-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg GRIFULVIN V griseofulvin, microsize SUSPENSION;ORAL 062483-001 Jan 26, 1984 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg ERTACZO sertaconazole nitrate CREAM;TOPICAL 021385-001 Dec 10, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Valeant Luxembourg GRIFULVIN V griseofulvin, microcrystalline TABLET;ORAL 062279-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Valeant Luxembourg

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene CAPSULE;ORAL 021055-001 Dec 29, 1999 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ➤ Subscribe ➤ Subscribe
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT LUXEMBOURG drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 75 mg ➤ Subscribe 6/6/2011

Non-Orange Book US Patents for Valeant Luxembourg

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,655,699 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors ➤ Subscribe
5,780,676 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors ➤ Subscribe
6,043,279 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors ➤ Subscribe
6,610,883 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors ➤ Subscribe
6,320,074 Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Valeant Luxembourg Drugs

Supplementary Protection Certificates for Valeant Luxembourg Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2001 Austria ➤ Subscribe PRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
C0027 France ➤ Subscribe PRODUCT NAME: BEXAROTENE; REGISTRATION NO/DATE: EU/1/01/178/001 20010329
00037 Netherlands ➤ Subscribe PRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
00054 Netherlands ➤ Subscribe PRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329
C013/2001 Ireland ➤ Subscribe SPC013/2001: 20031205, EXPIRES: 20160328
C/GB01/005 United Kingdom ➤ Subscribe PRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727
2001 00032 Denmark ➤ Subscribe
C/GB01/041 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
01C/010 Belgium ➤ Subscribe PRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
McKesson
Julphar
Argus Health
Fish and Richardson
Mallinckrodt
UBS
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot